Why the study?
Does purified ACE inhibit the aggregation and deposition of amyloid beta-peptide in vitro?
Does purified ACE inhibit the aggregation and deposition of amyloid beta-peptide in vitro?
Purified ACE inhibits the aggregation, fibril formation, and deposition of Alzheimer's amyloid beta-peptide in vitro, suggesting a potential protective mechanism against Alzheimer's disease.
In vitro Aβ inhibition by ACE is hypothesis-generating; leaves open relevance to Alzheimer's progression in vivo or clinically.
We have demonstrated that the angiotensin-converting enzyme (ACE) genotype is associated with Alzheimer's disease (AD) in the Japanese population (1). To determine why ACE affects susceptibility to AD, we examined the effect of purified ACE on aggregation of the amyloid -peptide (A) in vitro. Surprisingly, ACE was found to significantly inhibit A aggregation in a dose response manner. The inhibition of aggregation was specifically blocked by preincubation of ACE with an ACE inhibitor, lisinopril. ACE was confirmed to retard A fibril formation with electron microscopy. ACE inhibited A deposits on a synthaloid plate, which was used to monitor A deposition on autopsied brain tissue.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: